Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.63 |
| ▸ | TDP2 | O95551 | 6/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | CASP9 | P55211 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.49 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 2/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17086117 | 0.89 | TDP2 (0.52) | SRD5A2TDP2CASP3CASP7CASP9 | |
| SCHEMBL28385255 | 0.81 | SRD5A2 (0.53) | SRD5A2TDP2HPGDALDH1A1ALOX5 | |
| SCHEMBL29460235 | 0.78 | SRD5A2 (1.00) | SRD5A2SRD5A1HPGDALDH1A1CYP1A2 | |
| SCHEMBL3105349 | 0.78 | SRD5A2 (0.86) | SRD5A2TDP2SRD5A1HPGDALDH1A1 | |
| SCHEMBL503767 | 0.78 | SRD5A2 (1.00) | SRD5A2SRD5A1HPGDALDH1A1CYP1A2 | |
| SCHEMBL29709873 | 0.78 | SRD5A2 (0.86) | SRD5A2TDP2SRD5A1HPGDALDH1A1 | |
| SCHEMBL31069845 | 0.78 | SRD5A2 (0.86) | SRD5A2TDP2SRD5A1HPGDALDH1A1 | |
| SCHEMBL2087698 | 0.78 | TDP2 (0.66) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL3408012 | 0.78 | AHR (0.58) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL16126108 | 0.77 | SRD5A2 (0.84) | SRD5A2TDP2SRD5A1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-10968211-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2009075691-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | ACADIA PHARMACEUTICALS | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| WO-2007047737-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | SDHB, TFRC, SLC40A1 | SRD5A2 423/4885TDP2 4495/4885CASP3 3855/4885 |
| US-20070105819-A1 | CB-1 modulating compounds and their use | CNR1, CNR2, FAAH | SRD5A2 3147/4885TDP2 4197/4885CASP3 3067/4885 |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | SRD5A2 4118/4885TDP2 3753/4885CASP3 4353/4885 |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | SRD5A2 4044/4885TDP2 4096/4885CASP3 3780/4885 |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | SRD5A2 4044/4885TDP2 4096/4885CASP3 3780/4885 |
| US-10968211-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | SRD5A2 4044/4885TDP2 4096/4885CASP3 3780/4885 |
| US-11814376-B2 | Hepatitis b core protein modulators | HAVCR2, FABP1, MAVS | SRD5A2 4044/4885TDP2 4096/4885CASP3 3780/4885 |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | CNR1, CNR2, FAAH | SRD5A2 3147/4885TDP2 4197/4885CASP3 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.